Accessibility Menu
Maravai LifeSciences Stock Quote

Maravai LifeSciences (NASDAQ: MRVI)

$3.45
(1.0%)
+0.04
Price as of October 23, 2025, 3:31 p.m. ET

KEY DATA POINTS

Current Price
$3.45
Daily Change
(1.0%) +$0.04
Day's Range
$3.44 - $3.53
Previous Close
$3.41
Open
$3.43
Beta
0
Volume
492,083
Average Volume
1,440,283
Market Cap
493.4M
Market Cap / Employee
$3.41M
52wk Range
$1.67 - $8.29
Revenue
-
Gross Margin
0.25%
Dividend Yield
N/A
EPS
-$1.37
CAPs Rating
-
Industry
Life Sciences Tools and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Maravai LifeSciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
MRVI-56.73%N/AN/A-89%
S&P+14.5%+93.32%+14.09%+88%

Maravai LifeSciences Company Info

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$47.40M-35.4%
Gross Profit$7.17M-74.6%
Gross Margin15.12%-23.4%
Market Cap$346.98M-63.5%
Market Cap / Employee$0.61M0.0%
Employees570-12.3%
Net Income-$69.84M-381.9%
EBITDA-$13.08M-578.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$269.91M-52.9%
Accounts Receivable$27.88M-27.9%
Inventory46.7-5.3%

Liabilities

Q2 2025YOY Change
Long Term Debt$356.84M-35.0%
Short Term Debt$14.24M7.3%

Ratios

Q2 2025YOY Change
Return On Assets-16.61%-9.5%
Return On Invested Capital4.19%-3.9%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$13.14M-266.7%
Operating Free Cash Flow-$10.27M-158.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book3.412.240.961.15-50.10%
Price to Sales4.252.981.311.61-53.87%
Price to Tangible Book Value-41.27-27.07-10.62-5.90-19.62%
Price to Free Cash Flow TTM14.27-
Enterprise Value to EBITDA816.96-88.68-31.31-49.76-110.46%
Free Cash Flow Yield7.0%-
Return on Equity-52.0%-39.0%-45.8%-55.4%100.85%
Total Debt$561.08M$376.69M$326.65M$371.08M-33.96%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.